The Role of 18F-FDG PET/CT in Predicting Tumor Response after Preoperative Chemo-radiation Therapy for Rectal Cancer
W. Sun,Z. Zhang,J. Xu,W. Sheng,W. Hu,J. Zhu,G. Cai,W. Gu,Y. Xu,S. Cai
DOI: https://doi.org/10.1016/j.ijrobp.2011.06.592
2011-01-01
Abstract:Prediction of rectal cancer response to preoperative chemo-radiation therapy (CRT) provides the opportunity to perform individualized therapy. 18-Fluorine fluorodeoxyglucose positron emission tomography (18F-FDG PET), which can reflect intrinsic biological activity within tumor, is a promising tool for monitoring the effect of anti-tumor therapy. The aim of this study was to investigate the potential of sequential PET/CT in assessing and predicting of histopathological response to preoperative CRT of rectal cancer. 28 patients with T3-4 and/or N+ rectal cancer were enrolled between Jun 2009 and Dec 2010. All patients received preoperative CRT (pelvic radiation therapy: 50-55Gy/25Fx; concurrent chemotherapy using capecitabine and oxaliplatin) followed by radical surgery after 6-8 weeks. All patients underwent baseline 18F-FDG PET/CT scans within 1 week prior to the initiation of treatment (PET/CT1) and a second scan within 1 week after the completion of CRT (PET/CT2). 18 of the 28 patients also underwent a third PET/CT within 1 week prior to the surgery (PET/CT3). SUVmax, SUVmean, metabolic tumor volume (MV) and total lesion glycolysis (TLG, MV×SUVmean) were measured in each PET/CT imaging. Response indices (RI: percentage differences among PET/CT1, 2 and 3) of SUV, MV and TLG were calculated. The different metabolic parameters were analyzed and correlated with pathological treatment response. When patients were classified as pathological complete response (pCR) and non-pCR, significant differences in RI-MV(1-3) (59.86% vs. 84.79%, P = 0.005), RI-TLG(1-3) (73.46% vs. 91.45%, P = 0.007), RI-SUVmax(2-3) (-0.99% vs. 36.1%, P = 0.021) were observed between the two groups. When patients were classified into three groups (Group1: no residual tumor cells, pCR; Group2: rare residual tumor cells; Group3: others), significant differences in RI-MV(1-3) and RI-TLG(1-3) were also observed. RI-MV(1-3) ,RI-TLG(1-3) and RI-SUVmax(2-3) were significantly lower in Group1 than in Group2 (59.86% vs. 85.95%, P = 0.027; 73.46% vs. 91.71%, P = 0.027; -0.99% vs. 38.83%, P = 0.027). RI-MV(1-3) and RI-TLG(1-3) were also significantly lower in Group1 than in Group3 (59.86% vs. 84.28%, P = 0.009; 73.46% vs. 91.33%, P = 0.014) while RI-SUVmax(2-3) showed lower trend in Group1 than in Group3(-0.99% vs. 34.89%, P = 0.053). However, significant differences in these parameters were not observed between Group2 and Group3. The variation of 18F-FDG PET/CT has the potential of evaluating and predicting of preoperative CRT response in rectal cancer especially SUV combined with metabolic area volume. However, the utility of PET/CT to guide treatment decisions should be further explored in larger clinical studies.